[go: up one dir, main page]

GB202403366D0 - Product - Google Patents

Product

Info

Publication number
GB202403366D0
GB202403366D0 GBGB2403366.4A GB202403366A GB202403366D0 GB 202403366 D0 GB202403366 D0 GB 202403366D0 GB 202403366 A GB202403366 A GB 202403366A GB 202403366 D0 GB202403366 D0 GB 202403366D0
Authority
GB
United Kingdom
Prior art keywords
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2403366.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB2403366.4A priority Critical patent/GB202403366D0/en
Publication of GB202403366D0 publication Critical patent/GB202403366D0/en
Priority to PCT/EP2025/056345 priority patent/WO2025186463A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G01N33/5759—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GBGB2403366.4A 2024-03-08 2024-03-08 Product Ceased GB202403366D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2403366.4A GB202403366D0 (en) 2024-03-08 2024-03-08 Product
PCT/EP2025/056345 WO2025186463A1 (en) 2024-03-08 2025-03-07 Agents relating to the expression of cd61 on immune cells and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2403366.4A GB202403366D0 (en) 2024-03-08 2024-03-08 Product

Publications (1)

Publication Number Publication Date
GB202403366D0 true GB202403366D0 (en) 2024-04-24

Family

ID=90730968

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2403366.4A Ceased GB202403366D0 (en) 2024-03-08 2024-03-08 Product

Country Status (2)

Country Link
GB (1) GB202403366D0 (en)
WO (1) WO2025186463A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022853A1 (en) 1991-06-18 1992-12-23 Kodak Limited Photographic processing apparatus
WO2005113605A1 (en) 2004-05-19 2005-12-01 Celltech R & D Limited Cross-linked antibodies
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037176A (en) * 1999-06-25 2000-03-14 Isis Pharmaceuticals Inc. Antisense inhibition of integrin beta 3 expression
EP2025685B1 (en) * 2007-08-15 2013-06-19 Canadian Blood Services Monoclonal antibodies against BETA3 integrins
EP2203746B1 (en) * 2007-09-24 2013-03-06 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
EP2809682B1 (en) * 2012-02-03 2020-04-08 F.Hoffmann-La Roche Ag Bispecific antibody molecules with antigen-transfected t-cells and their use in medicine
TWI788307B (en) * 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992022853A1 (en) 1991-06-18 1992-12-23 Kodak Limited Photographic processing apparatus
WO2005113605A1 (en) 2004-05-19 2005-12-01 Celltech R & D Limited Cross-linked antibodies
WO2009040562A1 (en) 2007-09-26 2009-04-02 Ucb Pharma S.A. Dual specificity antibody fusions
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1999, WILEY INTERSCIENCE
"John Radcliffe Hospita", April 2021, COLD SPRING HARBOR PUBLISHING
ABD HAMID, M ET AL.: "Self-Maintaining CD103(+) Cancer-Specific T Cells Are Highly Energetic with Rapid Cytotoxic and Effector Responses", CANCER IMMUNOL RES, vol. 8, 2020, pages 203 - 216
BERTONI, A.ALABISO, O.GALETTO, A. SBALDANZI, G: "Integrins in T Cell Physiology", INT J MOL SCI, vol. 19, 2018, XP055757479, DOI: 10.3390/ijms19020485
CEPEK, K. L ET AL.: "Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin", NATURE, vol. 372, 1994, pages 190 - 193, XP002137720, DOI: 10.1038/372190a0
CHANCARTER, NATURE REVIEWS IMMUNOLOGY, vol. 10, May 2010 (2010-05-01), pages 301
CHEN, X ET AL.: "Requirement of open headpiece conformation for activation of leukocyte integrin alphaXbeta2", PROC NATL ACAD SCI U S A, vol. 107, 2010, pages 14727 - 14732, XP055401919, DOI: 10.1073/pnas.1008663107
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
CLUZEL, C ET AL.: "The mechanisms and dynamics of (alpha)v(beta)3 integrin clustering in living cells", J CELL BIOL, vol. 171, 2005, pages 383 - 392
CORGNAC, S ET AL.: "CD103(+)CD8(+) TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17", CELL REP MED, vol. 1, 2020, pages 100127, XP055956883, DOI: 10.1016/j.xcrm.2020.100127
D. HOLMES, NATURE REV DRUG DISC, vol. 10, November 2011 (2011-11-01), pages 798
DUHEN, T ET AL.: "Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors", NAT COMMUN, vol. 9, 2018, pages 2724
EDWARDS, J ET AL.: "CD103(+) Tumor-Resident CD8(+) T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment", CLIN CANCER RES, vol. 24, 2018, pages 3036 - 3045
GANESAN, A. P ET AL.: "Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer", NAT IMMUNOL, vol. 18, 2017, pages 940 - 950, XP055637852, DOI: 10.1038/ni.3775
GIANNI, T.LEONI, V.CHESNOKOVA, L. S.HUTT-FLETCHER, L. MCAMPADELLI-FIUME, G: "alphavbeta3-integrin is a major sensor and activator of innate immunity to herpes simplex virus-1", PROC NATL ACAD SCI U S A, vol. 109, 2012, pages 19792 - 19797
GUEGUEN, P ET AL.: "Contribution of resident and circulating precursors to tumor-infiltrating CD8(+) T cell populations in lung cancer", SCI IMMUNOL, vol. 6, 2021
HURRELL JGR: "Monoclonal Hybridoma Antibodies: techniques and applications", 1982, CRC PRESS
HYNES, R. O.RUOSLAHTI, ESPRINGER, T. A: "Reflections on Integrins-Past, Present, and Future: The Albert Lasker Basic Medical Research Award", JAMA, vol. 328, 2022, pages 1291 - 1292
HYNES, R. O: "Integrins: bidirectional, allosteric signaling machines", CELL, vol. 110, 2002, pages 673 - 687
LEFKOVITS, J.PLOW, E. FTOPOL, E. J: "Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine", N ENGL J MED, vol. 332, 1995, pages 1553 - 1559
MACKAY, L. K ET AL.: "The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin", NAT IMMUNOL, vol. 14, 2013, pages 1294 - 1301
MALIK, B. T ET AL.: "Resident memory T cells in the skin mediate durable immunity to melanoma", SCI IMMUNOL, vol. 2, 2017, XP093046127, DOI: 10.1126/sciimmunol.aam6346
MARKS ET AL., JMOL, BIOL., vol. 222, no. 3, 1991, pages 581 - 597
MOULDER, K.ROBERTS, K.SHEVACH, E. MCOLIGAN, J. E: "The mouse vitronectin receptor is a T cell activation antigen", J EXP MED, vol. 173, 1991, pages 343 - 347
NIIYA, K ET AL.: "Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation", BLOOD, vol. 70, 1987, pages 475 - 483
NUNEZ-PRADO ET AL.: "The coming of Age of Engineered Multivalent Antibodies", DRUG DISCOVERY TODAY, vol. 20, no. 5, March 2015 (2015-03-01), pages 588 - 594, XP029576646, DOI: 10.1016/j.drudis.2015.02.013
PAUL, B. Z.VILAIRE, G.KUNAPULI, S. PBENNETT, J. S: "Concurrent signaling from Galphaq- and Galphai-coupled pathways is essential for agonist-induced alphavbeta3 activation on human platelets", J THROMB HAEMOST, vol. 1, 2003, pages 814 - 820
QU, M ET AL.: "Platelet-derived microparticles enhance megakaryocyte differentiation and platelet generation via miR-1915-3p", NAT COMMUN, vol. 11, 2020, pages 4964
ROUKENS, A. H. E ET AL.: "Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2-specific CD8(+) T cell responses following COVID-19", NAT IMMUNOL, vol. 23, 2022, pages 23 - 32, XP037648909, DOI: 10.1038/s41590-021-01095-w
SZABO, P. A ET AL.: "Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19", IMMUNITY, vol. 54, 2021, pages 797 - 814
University of Oxford Animal Welfare; "Uniprot", Database accession no. UP000005640
VERMA ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, vol. 216, 1998, pages 165 - 181
WAGNER, C. L ET AL.: "Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets", BLOOD, vol. 88, 1996, pages 907 - 914
YANG, R ET AL.: "Distinct epigenetic features of tumor-reactive CD8+ T cells in colorectal cancer patients revealed by genome-wide DNA methylation analysis", GENOME BIOL, vol. 21, 2019, pages 2
ZUNDLER, S ET AL.: "Blockade of alphaEbeta7 integrin suppresses accumulation of CD8(+) and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo", GUT, vol. 66, 2017, pages 1936 - 1948, XP055493441

Also Published As

Publication number Publication date
WO2025186463A8 (en) 2025-10-02
WO2025186463A1 (en) 2025-09-12

Similar Documents

Publication Publication Date Title
GB202202060D0 (en) Product
GB2623583B (en) Construction Product
GB202511650D0 (en) Product
GB202511281D0 (en) Product
GB202510997D0 (en) Floorcare product
GB202510313D0 (en) Product
GB202508503D0 (en) Product
GB202507678D0 (en) Product
GB202506897D0 (en) Product
GB202506898D0 (en) Product
GB202504142D0 (en) Product
GB202418716D0 (en) Product
GB202417304D0 (en) Product
GB202416973D0 (en) Product
GB202416974D0 (en) Product
GB202414484D0 (en) Product
GB202408639D0 (en) Product
GB202403366D0 (en) Product
GB202400371D0 (en) Product
GB202405649D0 (en) Construction product
GB202304491D0 (en) Product
GB202304454D0 (en) Product
GB202302255D0 (en) Product
GB202218144D0 (en) Product
GB202216674D0 (en) Product

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)